9 Highly Anticipated FDA Decisions in Second Half of 2023

[cafead]

via The first half of 2023 saw some milestone FDA approvals, including a series of firsts in superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis, Rett Syndrome and Friedreich’s ataxia. The second half of this year could see at least four more—in Alzheimer’s disease, depression, sickle cell disease and advanced melanoma. BioSpace highlights eight FDA decisions to watch before the New Year.

article source